We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: COPD
MedXY News
EnglishTag

COPD

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Beyond the Golden Years: Young COPD and Early Lung Function Decline as Critical Drivers of Premature Mortality and Cardiovascular Risk
Internal Medicinecardiovascular riskCOPD

Beyond the Golden Years: Young COPD and Early Lung Function Decline as Critical Drivers of Premature Mortality and Cardiovascular Risk

By MedXY|Dec 31, 2025

Recent evidence reveals that COPD in adults under 50 is more prevalent than previously thought, significantly increasing the risk of premature death and heart failure. Furthermore, impaired lung function trajectories starting in childhood p

Smartphone-Based Pulmonary Rehabilitation Bridging the Gap in Chronic Respiratory Care: A Randomized Controlled and Feasibility Study
Family Medicine & NutritionCOPDdigital health

Smartphone-Based Pulmonary Rehabilitation Bridging the Gap in Chronic Respiratory Care: A Randomized Controlled and Feasibility Study

By MedXY|Dec 23, 2025

A randomized trial demonstrates that a smartphone app-based pulmonary rehabilitation program significantly improves quality of life and physical activity in patients with chronic respiratory diseases, offering a scalable alternative to trad

Bridging the Care Gap: Smartphone-Based Pulmonary Rehabilitation Enhances Quality of Life and Physical Activity in Chronic Respiratory Disease
Internal Medicinechronic respiratory diseaseCOPD

Bridging the Care Gap: Smartphone-Based Pulmonary Rehabilitation Enhances Quality of Life and Physical Activity in Chronic Respiratory Disease

By MedXY|Dec 23, 2025

A 12-week randomized controlled trial reveals that smartphone-based pulmonary rehabilitation significantly improves quality of life and physical activity in patients with chronic respiratory diseases, offering a scalable and feasible altern

Bridging the Gap after Pulmonary Rehabilitation: Evaluating the PICk UP Programme in COPD Management
Rehabilitation MedicineCOPDPhysical Activity

Bridging the Gap after Pulmonary Rehabilitation: Evaluating the PICk UP Programme in COPD Management

By MedXY|Oct 23, 2025

A randomized trial shows that a six-month personalised community-based physical activity programme sustains physical activity improvements and functional performance post-pulmonary rehabilitation in COPD patients, though other health benefi

Optimizing Exercise Progression in COPD with Chronic Respiratory Failure: Insights from a Pilot Trial of High Intensity Interval Training
Rehabilitation MedicineCOPDhigh-intensity interval training

Optimizing Exercise Progression in COPD with Chronic Respiratory Failure: Insights from a Pilot Trial of High Intensity Interval Training

By MedXY|Oct 23, 2025

This pilot randomized trial investigates the safety, feasibility, and efficacy of high intensity interval training modalities compared to constant-load endurance training in COPD patients with chronic respiratory failure, revealing promisin

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials
newsclinical trialCOPD

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

By MedXY|Oct 9, 2025

Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.

Mepolizumab in Preventing COPD Exacerbations in Patients with Eosinophilic Phenotype: Insights from the MATINEE Trial
newsCOPDEosinophilic Phenotype

Mepolizumab in Preventing COPD Exacerbations in Patients with Eosinophilic Phenotype: Insights from the MATINEE Trial

By MedXY|Oct 8, 2025

Mepolizumab significantly reduces moderate to severe COPD exacerbations in patients with elevated eosinophils on triple inhaled therapy, marking a promising advance for eosinophilic COPD management.

High-Flow Nasal Oxygen Reduces Hypoxaemia During Bronchoscopy in COPD: Insights from the PROSA 2 Randomised Trial
newsbronchoscopyCOPD

High-Flow Nasal Oxygen Reduces Hypoxaemia During Bronchoscopy in COPD: Insights from the PROSA 2 Randomised Trial

By MedXY|Oct 8, 2025

The PROSA 2 trial demonstrates that high-flow nasal oxygen significantly reduces hypoxaemia time and events compared to conventional low-flow oxygen in COPD patients undergoing bronchoscopy, improving procedural safety without compromising

Decoding COPD Heterogeneity: Airway Eosinophilia, Type 2 Inflammation, and Corticosteroid Responsiveness
newsCOPDinhaled corticosteroids

Decoding COPD Heterogeneity: Airway Eosinophilia, Type 2 Inflammation, and Corticosteroid Responsiveness

By MedXY|Oct 8, 2025

This study elucidates that airway eosinophilia in COPD is linked to enhanced type 2 inflammation in airway epithelium and predicts responsiveness to inhaled corticosteroids, revealing a distinct COPD endotype with potential for precision th

Low-Dose Morphine in COPD: Balancing Breathlessness Relief Against Sleep-Related Respiratory Risks
Clinical UpdatesCOPDmorphine

Low-Dose Morphine in COPD: Balancing Breathlessness Relief Against Sleep-Related Respiratory Risks

By MedXY|Oct 8, 2025

A randomized crossover trial reveals low-dose morphine in COPD does not improve sleep efficiency or breathlessness but may cause nocturnal hypoventilation, raising safety concerns despite unchanged next-day alertness.

Dupilumab Enhances Quality of Life and Relieves Respiratory Symptoms in COPD Patients with Type 2 Inflammation: Insights from BOREAS and NOTUS Trials
Clinical UpdatesCOPDdupilumab

Dupilumab Enhances Quality of Life and Relieves Respiratory Symptoms in COPD Patients with Type 2 Inflammation: Insights from BOREAS and NOTUS Trials

By MedXY|Oct 8, 2025

Add-on dupilumab significantly improves health-related quality of life and respiratory symptoms in COPD patients with type 2 inflammation, according to pooled results from the BOREAS and NOTUS phase 3 trials.

Sustained Alterations in Glutamate Metabolism After Resistance Exercise in Older Adults With COPD and Healthy Controls
Clinical UpdatesCOPDmuscle health

Sustained Alterations in Glutamate Metabolism After Resistance Exercise in Older Adults With COPD and Healthy Controls

By MedXY|Oct 8, 2025

Resistance exercise induces prolonged increases in glutamate production in older adults with COPD and healthy controls, highlighting unique metabolic adaptations that may influence pulmonary rehabilitation outcomes and muscle health.

Clinical UpdatesCOPDemphysema

Innovative Airway Scaffolds Demonstrate Safety and Efficacy in Reducing Hyperinflation in Severe Emphysema: Six-Month BREATHE Trial Results

By MedXY|Sep 19, 2025

The BREATHE trial reveals that novel self-expanding nitinol airway scaffolds are safe, feasible, and effective in reducing lung hyperinflation and improving symptoms in severe emphysema patients at six months post-implantation.

Targeting IL-33 in COPD: Insights from the Phase 2a FRONTIER-4 Trial of Tozorakimab
newsCOPDexacerbations

Targeting IL-33 in COPD: Insights from the Phase 2a FRONTIER-4 Trial of Tozorakimab

By MedXY|Oct 8, 2025

The FRONTIER-4 phase 2a trial evaluated tozorakimab, an anti-IL-33 monoclonal antibody, in moderate-to-severe COPD with chronic bronchitis. While the primary endpoint was unmet in the overall population, efficacy signals emerged in patients

Decoding Thoracoabdominal Asynchrony in Severe COPD: Insights Into Exercise Limitation and Respiratory Support
newsCOPDexercise

Decoding Thoracoabdominal Asynchrony in Severe COPD: Insights Into Exercise Limitation and Respiratory Support

By MedXY|Oct 8, 2025

This study reveals how thoracoabdominal asynchrony (TAA) during exercise reflects lung function severity and predicts breathlessness in very severe COPD patients, highlighting its potential to guide personalized respiratory support strategi

Evaluating Carbocysteine in Mild-to-Moderate COPD: Insights From a Large Multicenter Controlled Trial
newsCOPDexacerbations

Evaluating Carbocysteine in Mild-to-Moderate COPD: Insights From a Large Multicenter Controlled Trial

By MedXY|Oct 7, 2025

A large phase 4 trial found carbocysteine did not significantly reduce exacerbation rates or improve lung function in mild-to-moderate COPD, suggesting limited benefit beyond severe cases.

Nasal High Flow Therapy During Exercise in COPD: Incremental Gains in Dyspnoea and Endurance
Clinical UpdatesCOPDexercise

Nasal High Flow Therapy During Exercise in COPD: Incremental Gains in Dyspnoea and Endurance

By MedXY|Oct 2, 2025

Nasal high flow therapy modestly improves tidal volume and dyspnoea during exercise in severe COPD but has minimal effect on respiratory muscle workload or endurance capacity.

AI-Enhanced Spirometry Interpretation in Primary Care: Evidence from a Randomized Controlled Trial
Clinical Updatesartificial intelligenceCOPD

AI-Enhanced Spirometry Interpretation in Primary Care: Evidence from a Randomized Controlled Trial

By MedXY|Oct 1, 2025

AI decision support significantly improves primary care clinicians’ accuracy in spirometry diagnosis, especially for COPD, addressing a key gap in respiratory disease management.

Young COPD: Prevalence and Prognostic Impact in Adults Under 50 Years
Clinical UpdatesCOPDprevalence

Young COPD: Prevalence and Prognostic Impact in Adults Under 50 Years

By MedXY|Oct 1, 2025

COPD in adults under 50 affects 4.5% of this population and is linked to increased risks of early mortality and serious cardiopulmonary events, underscoring the need for early identification and intervention.

Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial
Clinical UpdatesbiomarkersCOPD

Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial

By MedXY|Oct 1, 2025

Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.

Prev
2 / 2
12
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities